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Insulin resistance and beta cell failure are major components of the pathogenesis of type 2 diabetes \[[@CR1]\]. In the past years, it has become apparent that adipose tissue is an endocrine organ that secretes adipokines affecting insulin sensitivity \[[@CR2]\]. Recently, retinol-binding protein 4 (RBP4) was identified as a new adipokine that links glucose uptake in adipocytes to systemic insulin resistance \[[@CR3]\].

Originally, RBP4 was known as the only transport protein for retinol \[[@CR4]\], but Yang et al. \[[@CR3]\] demonstrated a new function, by showing that adipose tissue-specific *Glut4* (also known as *Slc2a4*) knockout mice have increased serum levels of RBP4. Downregulation of GLUT4 in adipose tissue is an important feature of insulin resistance \[[@CR5]\]. RBP4 may be an important mechanistic link between downregulated GLUT4 in adipose tissue and systemic insulin resistance. This was confirmed in humans as well: RBP4 levels and the level of insulin resistance were correlated in people with obesity and impaired glucose tolerance, and in patients with type 2 diabetes \[[@CR6]\]. Moreover, RBP4 correlated with the level of insulin resistance in normoglycaemic men with a positive family history of type 2 diabetes, suggesting an underlying genetic predisposition. \[[@CR6]\]

In a Mongolian case--control study, four single nucleotide polymorphisms in the *RBP4* gene were associated with increased risk of type 2 diabetes \[[@CR7]\]. The *−803GA* polymorphism, located near an hepatic nuclear factor 1α (HNF1α)-binding motif, affects serum RBP4 levels and influences transcription efficiency and binding of HNF1α \[[@CR7]\]. So far, the relationship between genetic variants in the *RBP4* gene and type 2 diabetes risk has not been studied prospectively.

The mechanisms by which RBP4 affects insulin sensitivity are largely unknown. Yang et al. \[[@CR3]\] showed that RBP4 impaired muscle insulin signalling and increased the levels of phosphoenolpyruvate carboxykinase (PEPCK) in mouse liver. Whether these effects are based on retinol-dependent or -independent mechanisms is unclear.

The findings so far suggest that variation in the *RBP4* gene is involved in the pathogenesis of type 2 diabetes and that *RBP4* is a candidate gene for type 2 diabetes susceptibility. In a large prospective population-based study, we investigated the effect of the *RBP4 −803GA* polymorphism on type 2 diabetes risk. In addition, we assessed the association of retinol intake with risk of type 2 diabetes and its interaction with the *RBP4* polymorphism. Finally, we analysed the effect of the *RBP4* polymorphism on plasma vitamin A levels.

Methods {#Sec2}
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**Study population** Details of the Rotterdam Study have been described previously \[[@CR8]\]. In short, the Rotterdam Study is an ongoing prospective, population-based, cohort study in 7,983 inhabitants of a suburb in Rotterdam, designed to investigate determinants of chronic diseases in the elderly. Participants were aged 55 years or older. Baseline examinations were performed from 1990 until 1993. Follow-up examinations took place in 1993--1994, 1997--1999 and 2002--2004. Continuous surveillance on major disease outcomes was conducted between these examinations. Information on vital status was derived from municipal health authorities. The medical ethics committee of the Erasmus Medical Center approved the study protocol and all participants gave their written informed consent.

**Diabetes** In accordance with the guidelines of the World Health Organization \[[@CR9]\] and the American Diabetes Association \[[@CR10]\], diabetes was diagnosed at fasting plasma glucose levels ≥7.0 mmol/l and/or a non-fasting plasma glucose levels ≥11.0 mmol/l and/or treatment with antidiabetic medication (oral medication or insulin) and/or a diagnosis of diabetes as registered by a general practitioner. At baseline, prevalent cases of diabetes were diagnosed by a non-fasting or post-load glucose level (after OGTT) ≥11.1 mmol/l and/or treatment with antidiabetic medication (oral medication or insulin) and the diagnosis diabetes as registered by a general practitioner.

In the current study, patients diagnosed with type 1 diabetes according to the general practitioners' records were excluded. For the present study, baseline data were collected between 1990 and 1993.

**Genotyping** DNA material was available for genotyping of 6,571 participants. The *−803GA* polymorphism (rs3758539) in the *RBP4* gene was genotyped by means of a Taqman allelic discrimination assay. The assay was designed and optimised by Applied Biosystems (Foster City, CA, USA; <http://store.appliedbiosystems.com>). We genotyped 90 blood bank samples to test for adequate cloud separation. In the Rotterdam Study samples, 325 samples were genotyped in duplo, of which one gave an inconsistent result. To monitor contamination, 650 blank samples were incorporated on the plates, of which all gave a blank result. Reactions were performed on the Taqman Prism 7900HT platform. Genotyping was successful in 6,366 participants.

**Assessment of dietary and plasma levels of vitamin A** Dietary intake was assessed by means of an extensive, validated semiquantitative food-frequency questionnaire (SFFQ) \[[@CR11]\]. A trained dietitian interviewed the participants. The food and drink intake from the SFFQ were converted to energy and nutrient intake according to the Dutch Food Composition Table \[[@CR12]\]. In the current study, we used data on dietary intake of α-carotene (μg/day) and β-carotene (μg/day), β-cryptoxanthin (μg/day) and total energy (kJ/day). Alpha-carotene, β-carotene and β-cryptoxanthin were converted to retinol equivalents (RE; amount of RE = \[μg retinol\] + \[μg β-carotene/6\] + \[μg α-carotene/12\] + \[μg β-cryptoxanthin/12\] per day). Data on retinol intake were available for 5,642 participants.

Plasma levels of vitamin A were measured in a subgroup of 395 genotyped participants. At the second follow-up examination, blood samples were drawn after an overnight fast. Citrate plasma was immediately frozen and stored at −80°C. Total vitamin A plasma levels (retinol) were determined by a previously described method \[[@CR13]\]. Briefly, reversed-phase HPLC with UV detection was performed using an RP C18 Column 100 × 4.6 mm (Merck Lichrospher 100RP-18e; Merck, Darmstadt, Germany). Vitamin A was detected at 324 nm. The inter-assay CV was 4.0%.

**Statistical methods** Analyses were performed with SPSS software version 12.0.1. Continuous variables are expressed as means ± SEM. Comparisons between groups were performed with ANOVA and *χ*^2^ testing for normally distributed continuous and categorical variables, respectively. Deviation from Hardy--Weinberg equilibrium was assessed by means of *χ*^2^ testing.

We tested the association of the *RBP −803GA* polymorphism, RE intake and their interaction with type 2 diabetes risk in Cox proportional hazards models. Participants with prevalent type 2 diabetes at baseline were excluded from the analyses, since they may contain selection biases such as survival bias. For the polymorphism the additive, dominant or recessive model was chosen based on the genotypic test and the best-estimated log-likelihood statistic in univariate Cox proportional hazards regression. For the interaction analysis an interaction term was created by entering the product of the *−803GA* polymorphism and retinol intake to a model with both independent variables. All models were adjusted for year of birth and sex. Additional models were adjusted for BMI.

RE intake was adjusted for energy intake by saving the standardised residuals of a linear regression model with RE intake as dependent variable and total energy intake as independent variable. These standardised residuals represent the remaining variation in RE intake after correcting for energy intake. These standardised residuals were entered as an independent variable in subsequent models.

Results {#Sec3}
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*Baseline characteristics* In 6,320 successfully genotyped people, diabetes status was available. Of these, 658 had prevalent diabetes at baseline. Individuals whose DNA was not available or in whom genotyping did not succeed were 5.8 years older and contained 8.5% more women than the successfully genotyped group. This is explained by the fact that mostly elderly women in nursing homes did not provide DNA material for the study at baseline. Still, the genotyped and non-genotyped groups had similar distributions of BMI, waist circumference and presence of type 2 diabetes.

Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. Incident cases with type 2 diabetes were significantly younger, had higher BMI and waist circumference, lower HDL-cholesterol and more often hypertension than individuals without type 2 diabetes. As expected, prevalent cases were significantly older at baseline compared with incident cases (73.5 ± 0.35 vs 68.1 ± 0.32 years, *p* \< 0.001) and people without diabetes (73.5 ± 0.35 vs 69.0 ± 0.13 years, *p* \< 0.001). They were excluded from further analyses. Table 1Baseline characteristics of all genotyped participants, participants without diabetes and incident cases of type 2 diabetesCharacteristicAll participants (*n* = 6,320)Individuals without type 2 diabetes (*n* = 5,080)Incident cases with type 2 diabetes (*n* = 582)*p* value^a^Age (years)69.3 ± 0.1169.0 ± 0.1368.1 ± 0.320.02Men (%)40.640.544.00.10BMI (kg/m^2^)26.3 ± 0.0526.0 ± 0.0528.0 ± 0.16\<0.001Waist circumference (cm)90.5 ± 0.1589.6 ± 0.1694.7 ± 0.46\<0.001Systolic BP (mmHg)139.4 ± 0.3138.0 ± 0.3143.5 ± 0.9\<0.001Diastolic BP (mmHg)73.8 ± 0.273.7 ± 0.275.5 ± 0.5\<0.001Hypertension (%)33.630.746.7\<0.001Total cholesterol (mmol/l)6.6 ± 0.026.6 ± 0.026.6 ± 0.050.86HDL-cholesterol (mmol/l)1.34 ± 0.0051.37 ± 0.0051.25 ± 0.01\<0.001Current smoker (%)22.222.525.5Former smoker (%)40.842.242.10.18Continuous data are expressed as means ± SEM^a^*p* value for comparison between incident cases and individuals without diabetes

The polymorphism was in Hardy--Weinberg equilibrium in the total population and in individuals without type 2 diabetes (*χ*^2^ \< 1.02, *df* = 2, *p* \> 0.33). In the total population, we found 27.8% heterozygotes for the *−803GA* polymorphism, while 2.8% were homozygous for the *A* allele. These percentages were 26.1% and 5.0% and 28.1% and 2.6% in individuals with and without incident type 2 diabetes, respectively; *−803AA* 5.0% vs 2.6% for incident cases vs individuals without type 2 diabetes, *p* = 0.01.

The polymorphism was not associated with BMI, total cholesterol or HDL-cholesterol (data not shown).

*Cox proportional HRs for type 2 diabetes of the −803GA polymorphism* Based on the −log-likelihood values and genotype frequencies in individuals with and without type 2 diabetes, the recessive model of inheritance was the best-fitting model. Homozygosity for the *A* allele was associated with an HR of 1.83 (95% CI 1.26--2.66, *p* = 0.001) for type 2 diabetes compared with the reference group (*−803GG/GA*) adjusted for year of birth and sex. Figure [1](#Fig1){ref-type="fig"} shows the effect of the RBP4 *−803GA* genotypes on type 2 diabetes-free survival in our population. The association remained similar after additional adjustment for BMI (*−803AA* HR 1.81; 95% CI 1.25--2.64, *p* = 0.002; Table [2](#Tab2){ref-type="table"}). Fig. 1Diabetes-free survival rate according to *RBP4 −803GA* genotypes. Solid line, *GG*; dotted line, *GA*; dashed line, *AA*Table 2HRs for type 2 diabetes according to *RBP4 −803GA* genotypeGenotypeHR1^a^95% CI*p* valueHR2^b^95% CI*p* value*−803GG/GA*1.01.0*−803AA*1.831.26--2.660.0011.811.25--2.640.002^a^Adjusted for year of birth and sex^b^Adjusted for year of birth, sex and BMI

*RE intake, vitamin A plasma levels, the RBP4 polymorphism and risk of type 2 diabetes* RE intake corrected for energy intake was not associated with risk of type 2 diabetes (HR 1.0; 95% CI 1.0--1.0, *p* = 0.16) and did not interact with the *RBP4 −803GA* polymorphism on type 2 diabetes risk (HR 1.0; 95% CI 0.99--1.00, *p* for interaction = 0.35).

Vitamin A plasma level measurements were available in a subgroup of 395 genotyped participants. We did not observe significant differences between individuals with and without vitamin A plasma measurements with regards to BMI, waist circumference, sex and type 2 diabetes status. Individuals with measured vitamin A plasma levels were on average 4.3 years younger than those without vitamin A plasma measurements (65.4 ± 0.34 vs 69.7 ± 0.12 years, *p* \< 0.001), which is explained by the fact that they survived and participated until the second follow-up measurement. In this subgroup, the *RBP4* polymorphism was not significantly associated with vitamin A plasma levels (Table [3](#Tab3){ref-type="table"}). Table 3Plasma vitamin A levels according to *RBP4 −803GA* genotype*−803GAn*Vitamin A (μmol/l)GG2561.61 ± 0.02GA1291.59 ± 0.03AA101.64 ± 0.09
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RBP4 is a recently discovered adipokine that is thought to link adipocyte glucose metabolism to systemic insulin resistance \[[@CR3]\]. In the present study, we demonstrated that homozygosity for a promoter variant in the *RBP4* gene was associated with increased risk of type 2 diabetes at a population-based level. Vitamin A intake was not associated with type 2 diabetes and did not influence the relationship of the polymorphic variant with type 2 diabetes risk. In a subgroup analysis, the *RBP4* polymorphism was not significantly associated with vitamin A plasma levels.

Munkhtulga et al. \[[@CR7]\] were the first to describe the relationship between *RBP4* genetic variants and type 2 diabetes risk. Genotype frequencies for the *−803GA* polymorphism in this Mongolian population were approximately equal to the genotype frequencies in our white population. Similarly to our results, the *−803A* allele was associated with increased risk of type 2 diabetes. However, a dominant mode of inheritance was found as opposed to our finding of a recessive pattern. The difference in race and differences in exposure to environmental factors between the populations may explain the discrepancy. In two separate studies, white carriers of an *RBP4* haplotype had a significantly increased risk of type 2 diabetes \[[@CR14], [@CR15]\]. However, the individual *RBP4* polymorphisms were not related to risk of type 2 diabetes. In both studies, the haplotype associated with increased risk contained the *−803G* allele. This seems to contradict our findings, but the associated haplotype was not determined by the *−803GA* variant. The majority of the haplotypes found (four out of five) contained the *−803G* allele and were not associated with an increased risk, which makes it unlikely that the *G* allele contributed to the observed effect. The relatively small sample size of the study by Craig et al. \[[@CR14]\] and the presence of considerably younger controls than cases in the study by Kovacs et al. \[[@CR15]\] might have hidden the effect of the individual polymorphism. Hence, the findings in our large follow-up study do not necessarily contradict the two previous case--control studies: multiple *RBP4* variants may affect type 2 diabetes risk, including variants captured by the haplotypes described in the other references \[[@CR14], [@CR15]\], or by the *−803GA* polymorphism itself.

Since RBP4 is the only known retinol transport protein, a retinol-dependent mechanism underlying its effect on type 2 diabetes risk seems a reasonable assumption. Within tissues, retinol is activated to retinoic acid isomers, which have a wide array of pleiotropic effects through interaction with retinoid acid X receptors (RXRs) and retinoic acid receptors \[[@CR16]\], regulating transcription of over 300 target genes \[[@CR17]\]. Consistent with a retinol-dependent mechanism Yang et al. \[[@CR3]\] found that *RBP4* increased *PEPCK* expression in mouse liver and cultured hepatocytes. PEPCK is a gluconeogenic enzyme and retinoids regulate its transcription \[[@CR18]\]. All retinoids in the body originate from the diet \[[@CR19], [@CR20]\]. We did not find an association of retinol intake with type 2 diabetes risk. Conflicting results concerning this relationship have been published \[[@CR21]--[@CR25]\]. We did not observe interaction between retinol intake and the *RBP4* polymorphism on type 2 diabetes risk, nor did we find an association of the polymorphism with vitamin A plasma levels. However, since the effect on type 2 diabetes risk was confined to the *−803A* homozygotes and the analyses with vitamin A plasma levels contained only a small number of *−803A* homozygotes (*n* = 10), these results should be interpreted with caution. Compared with the other genotypes, the *−803A* homozygotes had a slightly higher mean plasma vitamin A level, although not significant. Therefore we cannot exclude the possibility that a retinol-dependent mechanism underlies the effect on type 2 diabetes risk. Moreover, the relationship between metabolites of retinol and insulin sensitivity may be complex, as some retinoic acids are thought to cause insulin resistance \[[@CR26], [@CR27]\], whereas others seem protective through RXR--peroxisome proliferator-activated receptor γ-activated pathways \[[@CR28]\]. Based on our results we cannot exclude that RBP4 alters the amount of specific retinoic acid isomers locally or systemically. However, a number of retinol-independent mechanisms may operate: RBP4 may increase type 2 diabetes risk by binding of cell surface receptors \[[@CR29], [@CR30]\], such as megalin and Stra6. Recently, it was shown that RBP4 can directly affect insulin signalling by blocking the insulin-stimulated phosphorylation of IRS-1 \[[@CR31]\]. Furthermore, RBP4 may modulate transthyretin function. Transthyretin was recently shown to be involved in beta cell stimulus--secretion coupling \[[@CR32], [@CR33]\].

The relationship between genetic variation in the *RBP4* gene and type 2 diabetes had not previously been investigated prospectively at a population-based level. We identified all incident cases of type 2 diabetes in this our large population-based study during a long period of follow-up. The availability of data on retinol intake in all individuals and vitamin A plasma levels in a subgroup allowed us to investigate potential associations and interactions between *RBP4* genetic variation and these parameters. To the best of our knowledge, this is the first study to examine this interaction.

In a previous study *−803GA* polymorphism was identified as a functional variant that affects HNF1α binding, *RBP4* transcription efficiency and RBP4 plasma levels. Unfortunately, RBP4 plasma levels in the Rotterdam Study are not available because of limitations in sample availability and lack of a readily available and reliable method to measure these levels in large populations and people with insulin resistance \[[@CR34]\]. Kovacs et al. did not find an effect of the *−803GA* polymorphism on serum RBP4 levels in a case--control study \[[@CR15]\]. Future studies are needed to obtain insight in the relationship between RBP4 serum levels and the genetic variation in the *RBP4* gene.

In conclusion, we have shown prospectively that a promoter polymorphism in the *RBP4* gene is associated with increased risk of type 2 diabetes in the Rotterdam population. Along with previous functional data our finding increases the confidence that the promoter polymorphism is a causal variant. Dietary intake of retinol did not influence type 2 diabetes risk or the association of the *RBP4* polymorphism with type 2 diabetes risk. Moreover, the *RBP4* polymorphism was not significantly associated with circulating vitamin A levels. However, we could not exclude a retinol-dependent mechanism underlying the association with type 2 diabetes.

The Rotterdam Study is supported by the Erasmus Medical Center and Erasmus University Rotterdam; the Netherlands Organization for Scientific Research; the Netherlands Organization for Health Research and Development (ZonMw); the Research Institute for Diseases in the Elderly; the Ministry of Education, Culture and Science; the Ministry of Health, Welfare and Sports; the European Commission; and the Municipality of Rotterdam.

**Duality of interest** The authors declare that there is no duality of interest associated with this manuscript.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

HNF1α

:   hepatic nuclear factor 1α

PEPCK

:   phosphoenolpyruvate carboxykinase

RBP4

:   retinol-binding protein 4

RE

:   retinol equivalent

RXR

:   retinoid acid X receptor
